

? b 155

14mar03 13:31:40 User208669 Session D22230.1

\$0.28 0.081 DialUnits File1

\$0.28 Estimated cost File1

\$0.28 Estimated cost this search

\$0.28 Estimated total session cost 0.081 DialUnits

File 155:MEDLINE(R) 1966-2003/Mar W2

(c) format only 2003 The Dialog Corp.

Set Items Description

--- -----

? s cmv or hcmv or cytomegalov?

10283 CMV

2213 HCMV

24750 CYTOMEGALOV?

S1 26949 CMV OR HCMV OR CYTOMEGALOV?

? s vaccine or vaccines

70977 VACCINE

63494 VACCINES

S2 99891 VACCINE OR VACCINES

? s s1 and s2

26949 S1

99891 S2

S3 742 S1 AND S2

? s dt=review?

S4 921605 DT=REVIEW?

? s s3 and s4

742 S3

921605 S4

S5 182 S3 AND S4

? t s5/7/4 7 9 11

5/7/4

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

14382961 22187601 PMID: 12199616

Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection.

Pass Robert F; Burke Rae Lyn; et al

Department of Pediatrics, University of Alabama School of Medicine, Birmingham, USA. rpass@peds.uab.edu

Seminars in pediatric infectious diseases (United States) Jul 2002, 13

(3) p196-204, ISSN 1045-1870 Journal Code: 9008093

Contract/Grant No.: AI-43681; AI; NIAID; +

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Congenital cytomegalovirus (CMV) infection is an important cause of hearing, cognitive, and motor impairments that cannot be effectively prevented or treated by any current medical or public health interventions.

A review of priorities for vaccine development by The Institute of Medicine of the National Academy of Sciences concluded that a vaccine to prevent congenital CMV infection should be a top priority for the United States.

Evidence from clinical studies indicates that immunity to CMV can reduce the frequency and severity of disease. Laboratory investigations have identified structural and nonstructural CMV proteins that play a key role in eliciting protective immunity. The rationale for development of a CMV vaccine has been strengthened further by studies in experimental animals demonstrating the ability of immunization with subunit vaccines to prevent disease and transplacental transmission of virus. At least 4 CMV vaccines are in clinical trials, and advances in biotechnology are paving the way for additional novel vaccines. (75 Refs.)

Record Date Created: 20020829

5/7/7

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

14134002 22249129 PMID: 12361753

Is there a formula for an effective CMV vaccine?

Plotkin Stanley A; et al

University of Pennsylvania, Wistar Institute, Aventis Pasteur, Doylestown, PA 18901, USA. stanley.plotkin@aventis.com

Journal of clinical virology - the official publication of the Pan

American Society for Clinical Virology (Netherlands) Aug 2002, 25 Suppl

2 pS13-21, ISSN 1386-6532 Journal Code: 9815671

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

(90 Refs.)

Record Date Created: 20021003

5/7/9

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

13739235 22165697 PMID: 12176855

Vaccines against persistent DNA virus infections.

Wills M R; Carmichael A J; Sissons J G P

Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK.

British medical bulletin (England) 2002, 62 p125-38, ISSN 0007-1420

Journal Code: 0376542

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Persistent viruses present some particular problems for vaccine design. As for acute non-persistent viruses, the prime goal of a vaccine should be to prevent primary infection. Vaccines might also be used to modify the course of established persistent virus infections - so-called postinfective immunisation. This chapter deals with selected persistent DNA viruses, in particular the human herpes viruses. (52 Refs.)

Record Date Created: 20020814

5/7/11

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

13568087 21929822 PMID: 11932137

DNA vaccines against cytomegalovirus: current progress.

Temperton N J

Academic Centre for Travel Medicine and Vaccines, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. rfuchdavaccine@hotmail.com

International journal of antimicrobial agents (Netherlands) Mar 2002,

19 (3) p169-72, ISSN 0924-8579 Journal Code: 9111860

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The development of a vaccine for the prevention of primary cytomegalovirus (CMV) infection is a major public health priority. Live attenuated virus, recombinant viral vector, recombinant protein and peptide vaccines have been studied as potential vaccine candidates. In recent years, DNA vaccination strategies have been developed for many pathogens, including CMV. This review aims to bring together many aspects of this relatively new vaccine technology as applied to current research into the development of vaccines against CMV. (37 Refs.)

Record Date Created: 20020404

7 s py>2000

S6 1125827 PY>2000

7 s s5 not s6

182 S5

1125827 S6

S7 153 S5 NOT S6

71 s77/9 12 14

77/9

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10492948 20007582 PMID: 10539854

Cytomegalovirus vaccine.

Plotkin S A

Pasteur Merieux Connaught, France.

American heart journal (UNITED STATES) Nov 1999, 138 (5 Pt 2) pS484-7, ISSN 0002-8703 Journal Code: 0370465

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Congenital cytomegalovirus disease is an unsolved public health problem, unlikely to be solved by means other than immune prophylaxis. Development of a vaccine has been hampered by low awareness of the problem, which is caused by the often delayed detection of abnormalities after birth. Nevertheless, cytomegalovirus vaccine development is active. An attenuated, live vaccine has been studied extensively, and an improved strain may result from genetic manipulation. An immunogenic viral glycoprotein (gB) vaccine is currently in clinical trial to determine if antibodies alone will be protective. The idea of a combined vaccine has been proposed, in which a canarypox recombinant containing several cytomegalovirus genes is used both to generate cellular immunity and to prime for augmented antibody responses to the viral glycoprotein. Finally, DNA plasmids containing cytomegalovirus genes are being investigated for their utility as vaccines. (42 Refs.)

Record Date Created: 19991202

7/7/12

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10366437 99358457 PMID: 10429809

[Vaccines against cytomegalovirus infect. Perspectives]

Vaccins contre les infections a cytomegalovirus. Perspectives.

Cadoz M; Meric C

Pasteur Merieux Connaught, Marcy-l'Etoile, France.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (FRANCE) 1999, 6 Suppl 3 p655s-658s, ISSN 0929-693X Journal Code: 9421356

Document type: Journal Article; Review; Review, Tutorial

Languages: FRENCH

Main Citation Owner: NLM

Record type: Completed

(16 Refs.)

Record Date Created: 19990824

7/7/14

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10237396 99215005 PMID: 10198792

Herpesvirus vaccines. Development, controversies, and applications.

Krause P R; Straus S E
 Food and Drug Administration, Center for Biologics Evaluation and
 Research, Office of Vaccines Research and Review, Bethesda, Maryland, USA.
 Infectious disease clinics of North America (UNITED STATES) Mar 1999,
 13 (1) p61-81, vi, ISSN 0891-5520 Journal Code: 8804508
 Document type: Journal Article; Review; Review, Tutorial
 Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Herpesviruses present difficult challenges in vaccine development because
 of their ability to evade immune clearance. Data and recommendations
 regarding the live-attenuated varicella vaccine are discussed. Approaches
 to developing vaccines to prevent herpes simplex virus (HSV),
 cytomegalovirus (CMV), and Epstein-Barr virus (EBV)-associated illnesses
 also are considered. (88 Refs.)

Record Date Created: 19990708

? log hold

14mar03 13:39:24 User208669 Session D2230.2

\$4.42 1.383 DialUnits File155

\$0.00 40 Type(s) in Format 6

\$1.47 7 Type(s) in Format 7

\$1.47 47 Types

\$5.89 Estimated cost File155

\$1.86 TELNET

\$7.75 Estimated cost this search

\$8.03 Estimated total session cost 1.463 DialUnits

Logoff: level 02.12.60 D 13:39:24